Immatics N.V. (IMTX) News
Filter IMTX News Items
IMTX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest IMTX News From Around the Web
Below are the latest news stories about IMMATICS NV that investors may wish to consider to help them evaluate IMTX as an investment opportunity.
Immatics N.V. (NASDAQ:IMTX) Reported Earnings Last Week And Analysts Are Already Upgrading Their EstimatesImmatics N.V. ( NASDAQ:IMTX ) defied analyst predictions to release its third-quarter results, which were ahead of... |
Immatics Sees Revenue Surge Despite R&D ExpensesImmatics (IMTX) has released an update. Immatics reported a significant increase in collaboration revenue for the nine months ending September 30, 2024, reaching €99.6 million compared to €38.1 million in the same period last year. Despite higher revenue, the company faced substantial research and development expenses, which contributed to a loss before taxes of €2.4 million for Q3 2024. Investors should note the company’s ongoing focus on R&D, which may impact financial performance in the near |
Immatics Announces Third Quarter 2024 Financial Results, Business Update and First Clinical Data on TCER® IMA402 Targeting PRAMEThe Company will now target five major cancer types with its four clinically active compounds across both TCR-T cell therapies and TCR-based Bispecifics Today, Company discloses first clinical data from the TCR Bispecific molecule, TCER® IMA402 targeting PRAME, in the Phase 1 dose escalation trial, demonstrating a favorable tolerability profile and signs of dose-dependent and PRAME expression-dependent clinical activity, including first objective responses in melanoma patients; early pharmacokin |
Immatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAMETwo oral presentations and multiple posters on clinical andpreclinical-stage candidates to be presented at SITC, demonstratingthe strength of Immatics’ TCR-T PRAME franchise to target solid cancers ACTengine® IMA203 demonstrates 54% cORR, 12.1 months mDOR and 6 months mPFS in heavily pretreated metastatic melanoma patients and >1-year mPFS in patients with deep responses; Company plans to start its randomized-controlled Phase 3 SUPRAME trial in December 2024 to evaluate IMA203 in second-line or |
Immatics N.V. (NASDAQ:IMTX) is a favorite amongst institutional investors who own 50%Key Insights Significantly high institutional ownership implies Immatics' stock price is sensitive to their trading... |
Immatics Advances IMA203 to Phase 3 Trial in MelanomaImmatics (IMTX) has released an update. Immatics has reported promising updated Phase 1b clinical data for its ACTengine IMA203 therapy targeting PRAME in metastatic melanoma, with a 54% objective response rate and median duration of response over 12 months. Following favorable Phase 1b outcomes, including 6 months median progression-free survival (PFS) and overall survival not yet reached, Immatics is advancing to a Phase 3 trial, SUPRAME, to further assess IMA203’s efficacy. The SUPRAME trial |
Immatics Announces Pricing of $150 Million Public OfferingHouston, Texas and Tuebingen, Germany, October 10, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, announced today the pricing of its previously announced underwritten public offering of 16,250,000 ordinary shares at a public offering price of $9.25 per share. The gross proceeds from the offering, before deducting the underwriting discount and offering expenses, are e |
Immatics Announces Proposed $150 Million Public OfferingHouston, Texas and Tuebingen, Germany, October 10, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, announced today the commencement of an underwritten public offering of its ordinary shares. The offering is subject to market conditions and other factors, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or term |
Immatics Announces Updated Phase 1b Clinical Data on ACTengine® IMA203 TCR-T Targeting PRAME in Melanoma Patients and Provides Update on Upcoming SUPRAME Phase 3 TrialCompany to host conference call and webcast today, October 10, at 9:00 am EDT/3:00 pm CEST Company announces updated Phase 1b clinical data on ACTengine® IMA203 targeting PRAME in 28 heavily pretreated metastatic melanoma patients with substantially enhanced maturity compared to the last data update in May 2024 and provides the first report on progression-free survival (PFS) and overall survival (OS)Based on the Phase 1b data, the Company will proceed directly to a registration-enabling Phase 3 |
Immatics N.V. (IMTX) Receives Buy Rating from AnalystsWe recently published a list of 10 Best Biotech Stocks To Buy Under $20. In this article, we are going to take a look at where Immatics N.V. (NASDAQ:IMTX) stands against the other best biotech stocks to buy under $20. The biotechnology industry is experiencing rapid growth, driven by increasing demand for innovative treatments, technological […] |